PHARMASAGA (TPEx Emerging Stock Market: 7878) announced on MOPS that the trial amendment for PS1-II-201, its Phase 2 clinical trial of PS1 in type 2 diabetes, submitted to the U.S. FDA, has passed the FDA's 30-day IND review period. The company will continue to advance the PS1-II-201 trial.
How can a Taiwan-developed diabetes drug connect with European research expertise? 🔬
We are committed to timely and transparent disclosure. For complete and accurate details, please refer to the official announcement on MOPS.Follow our page for further public updates. 📌
Pharmasaga (Taiwan Emerging Stock Market: 7878) announced on October 1 that it has completed the submission of an Investigational New Drug (IND) application to the US FDA for PS1-II-201, a Phase 2 clinical trial of PS1 on type 2 diabetes.
Pharmasaga Takes the Stage at Silicon Valley's Taiwan Venture Day, Featured in On-Site Interview by Epoch Times
Pharmasaga is proud to announce that we have recently been featured in an in-depth report by Sparknify, a premier Silicon Valley-based tech media platform and innovation ecosystem operator. As one of the few Asian biotech startups highlighted by Sparknify, this feature marks a significant milestone in our international visibility.
Globally, over 589 million people suffer from diabetes, making it one of the most critical chronic diseases worldwide. However, current treatments primarily focus on controlling blood sugar levels and struggle to restore damaged pancreatic beta-cell function. The market urgently needs next-generation therapies capable of targeting the disease's...
Global Pharmaceutical Companies Show Strong Interest in PS1 as Pharmasaga Advances International Licensing and Co-development Opportunities
